60 Degrees Pharmaceuticals Regains Nasdaq Compliance, Averting Delisting

summarizeSummary

60 Degrees Pharmaceuticals announced it has regained compliance with Nasdaq's minimum bid price rule, leading to the cancellation of its delisting hearing and ensuring its continued listing on The Nasdaq Capital Market.

check_boxKey Events

• Regains Nasdaq Compliance

  The company was notified on February 11, 2026, that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

• Delisting Hearing Cancelled

  As a result of regaining compliance, the delisting hearing before the Nasdaq Hearings Panel, previously scheduled for February 19, 2026, has been cancelled, and the matter is now closed.

• Continued Nasdaq Listing

  The company's common stock and warrants will continue to be listed and traded on The Nasdaq Capital Market, reversing the prior delisting determination from January 23, 2026.

auto_awesomeAnalysis

This filing is highly significant as it announces that 60 Degrees Pharmaceuticals has successfully regained compliance with Nasdaq's minimum bid price requirement, thereby avoiding delisting. This positive development directly reverses the critical delisting notice received on January 23, 2026, which had posed an immediate threat to the company's stock exchange listing. The cancellation of the scheduled delisting hearing removes a major overhang and provides stability for the company, especially following its recent 1-for-4 reverse stock split on January 21, 2026, which was likely implemented to help achieve this compliance. Maintaining a Nasdaq listing is crucial for investor confidence and access to capital markets for a company of this size.